Improving outcomes in opiate dependence by understanding barriers and facilitators to opiate detoxification.

In 2021, approximately half of all drug poisoning mortalities in England involved an opiate, the highest number since records began. With a decline in completed opioid detoxes (i.e. dose reduction and cessation of use),the need for new medications to support abstinence isurgent. Research in this area is underfunded and neglected.

The addiction team at Imperial College is the only group in the UK conducting research into new pharmacological targets for the treatment of opioid dependence. The FORWARDS study aims to investigate the safety and
efficacy of baclofen to support detoxification from methadone. To inform and optimise the implementation of novel treatments, it is crucial to first understand why the number of completed detoxes is declining, participant
motivations for recovery, and potential barriers to abstinence.

My project aims to identify key facilitators and barriers to the treatment of opioid addiction. It would use a mixed-method approach, analysing data from questionnaires, semi-structured interviews, and current literature. It is
hoped the study would offer an understanding as to why the number of completed detoxes is declining, and what can be done to support those wishing to detox or whose health may improve if abstinent. Findings would add huge
value to the trial by aiding the interpretation of efficacy data, and can be embedded into future clinical and research practice